Genetically Engineered Mice As Experimental Tools to Dissect the Critical Events in Breast Cancer

Overview

Journal Adv Cancer Res

Publisher Elsevier

Specialty Oncology

Date 2014 Jun 4

PMID 24889535

Citations 19

Authors

Mitchell E Menezes

Swadesh K Das

Luni Emdad

Jolene J Windle

Xiang-Yang Wang

Devanand Sarkar

Paul B Fisher

Affiliations

Soon will be listed here.

Abstract

Elucidating the mechanism of pathogenesis of breast cancer has greatly benefited from breakthrough advances in both genetically engineered mouse (GEM) models and xenograft transplantation technologies. The vast array of breast cancer mouse models currently available is testimony to the complexity of mammary tumorigenesis and attempts by investigators to accurately portray the heterogeneity and intricacies of this disease. Distinct molecular changes that drive various aspects of tumorigenesis, such as alterations in tumor cell proliferation and apoptosis, invasion and metastasis, angiogenesis, and drug resistance have been evaluated using the currently available GEM breast cancer models. GEM breast cancer models are also being exploited to evaluate and validate the efficacy of novel therapeutics, vaccines, and imaging modalities for potential use in the clinic. This review provides a synopsis of the various GEM models that are expanding our knowledge of the nuances of breast cancer development and progression and can be instrumental in the development of novel prevention and therapeutic approaches for this disease.

Citing Articles

Characterization of Mammary Tumors Arising from MMTV-PyVT Transgenic Mice.

Liu C, Huang W, Cheng S, Chen M, Lin C, Chang S Curr Issues Mol Biol. 2023; 45(6):4518-4528.

PMID: 37367035 PMC: 10297447. DOI: 10.3390/cimb45060286.

Bioassay-Guided extraction of andrographis paniculata for intervention of in-vitro prostate cancer progression in metabolic syndrome environment.

Idris M, Hasham R, Ismail H Daru. 2022; 30(2):253-272.

PMID: 35922691 PMC: 9715910. DOI: 10.1007/s40199-021-00414-8.

Conversion of a Non-Cancer-Selective Promoter into a Cancer-Selective Promoter.

Bhoopathi P, Pradhan A, Kumar A, Maji S, Mannangatti P, Deng X Cancers (Basel). 2022; 14(6).

PMID: 35326649 PMC: 8946048. DOI: 10.3390/cancers14061497.

A common goal to CARE: Cancer Advocates, Researchers, and Clinicians Explore current treatments and clinical trials for breast cancer brain metastases.

Joe N, Hodgdon C, Kraemer L, Redmond K, Stearns V, Gilkes D NPJ Breast Cancer. 2021; 7(1):121.

PMID: 34521857 PMC: 8440644. DOI: 10.1038/s41523-021-00326-5.

Alzheimer's Disease, and Breast and Prostate Cancer Research: Translational Failures and the Importance to Monitor Outputs and Impact of Funded Research.

Pistollato F, Bernasconi C, McCarthy J, Campia I, Desaintes C, Wittwehr C Animals (Basel). 2020; 10(7).

PMID: 32674379 PMC: 7401638. DOI: 10.3390/ani10071194.

References

Xu X, Wagner K, Larson D, Weaver Z, Li C, Ried T . Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet. 1999; 22(1):37-43. DOI: 10.1038/8743. View

Siegel P, Dankort D, Hardy W, Muller W . Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol. 1994; 14(11):7068-77. PMC: 359240. DOI: 10.1128/mcb.14.11.7068-7077.1994. View

Cho A, Haruyama N, Kulkarni A . Generation of transgenic mice. Curr Protoc Cell Biol. 2009; Chapter 19:Unit 19.11. PMC: 3119260. DOI: 10.1002/0471143030.cb1911s42. View

Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View

Spandidos D . Oncogene activation in malignant transformation: a study of H-ras in human breast cancer. Anticancer Res. 1987; 7(5B):991-6. View

Taneja P, Frazier D, Kendig R, Maglic D, Sugiyama T, Kai F . MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Rev Mol Diagn. 2009; 9(5):423-40. PMC: 2759974. DOI: 10.1586/erm.09.31. View

Boxer R, Jang J, Sintasath L, Chodosh L . Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell. 2004; 6(6):577-86. DOI: 10.1016/j.ccr.2004.10.013. View

Cardiff R, Kenney N . Mouse mammary tumor biology: a short history. Adv Cancer Res. 2007; 98:53-116. DOI: 10.1016/S0065-230X(06)98003-8. View

Shibata M, Maroulakou I, Jorcyk C, Gold L, Ward J, Green J . p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Res. 1996; 56(13):2998-3003. View

10.

Deng C, Scott F . Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene. 2000; 19(8):1059-64. DOI: 10.1038/sj.onc.1203269. View

11.

Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C . Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994; 54(7):1812-7. View

12.

Howe L, Subbaramaiah K, Patel J, Masferrer J, Deora A, Hudis C . Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res. 2002; 62(19):5405-7. View

13.

HAND P, Thor A, Wunderlich D, Muraro R, Caruso A, Schlom J . Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas. Proc Natl Acad Sci U S A. 1984; 81(16):5227-31. PMC: 391671. DOI: 10.1073/pnas.81.16.5227. View

14.

Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, Kong Y . Requirement for CDK4 kinase function in breast cancer. Cancer Cell. 2006; 9(1):23-32. DOI: 10.1016/j.ccr.2005.12.012. View

15.

Li M, Lewis B, Capuco A, Laucirica R, Furth P . WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis. Oncogene. 2000; 19(8):1010-9. DOI: 10.1038/sj.onc.1203271. View

16.

Tzeng Y, Guhl E, Graessmann M, Graessmann A . Breast cancer formation in transgenic animals induced by the whey acidic protein SV40 T antigen (WAP-SV-T) hybrid gene. Oncogene. 1993; 8(7):1965-71. View

17.

Ray D, Terao Y, Christov K, Kaldis P, Kiyokawa H . Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesis. Neoplasia. 2011; 13(5):439-44. PMC: 3084620. DOI: 10.1593/neo.101704. View

18.

Cardiff R, Anver M, Gusterson B, Hennighausen L, Jensen R, Merino M . The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene. 2000; 19(8):968-88. DOI: 10.1038/sj.onc.1203277. View

19.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

20.

Ahmed F, Wyckoff J, Lin E, Wang W, Wang Y, Hennighausen L . GFP expression in the mammary gland for imaging of mammary tumor cells in transgenic mice. Cancer Res. 2002; 62(24):7166-9. View